Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed evolving administration strategies for multiple myeloma therapies, primarily focusing on subcutaneous and on-body administration. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a clinical member of the Cancer Prevention, Control and Population Research Program at Case Comprehensive Cancer Center in Ohio. Dr Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Rochester, Minnesota.

In the first episode of a 3-part series, Drs Faiman and Ailawadhi outlined the transition to subcutaneous administration of anti-CD38 monoclonal antibodies in multiple myeloma management. They also highlighted the significance of the July 2026 FDA approval of satuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications, which includes administration with the CirCLIQ on-body delivery system.